The good fat hormone: Adiponectin and cardiovascular disease

Current Atherosclerosis Reports

Volumn 8, Issue 2, 2006, Pages 94-99

  Do, Dat ^b   Alvarez, Jorge ^b   Chiquette, Elaine ^b   Chilton, Robert ^a  

^a SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ADIPONECTIN RECEPTOR 1; ADIPONECTIN RECEPTOR 2; ALCOHOL; ALDOSTERONE; ANGIOTENSIN; C REACTIVE PROTEIN; CHOLESTEROL ESTER; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HIGH DENSITY LIPOPROTEIN; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; INTERCELLULAR ADHESION MOLECULE 1; NITRIC OXIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLINOSITOL 3 KINASE; PIOGLITAZONE; PLACEBO; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; RENIN; RIMONABANT; ROSIGLITAZONE; TROGLITAZONE; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1; VERY LOW DENSITY LIPOPROTEIN;

ADENOVIRUS VECTOR; ADIPOCYTE; ALCOHOL CONSUMPTION; ANGIOGENESIS; ANTIINFLAMMATORY ACTIVITY; ARTERY ENDOTHELIUM; ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL STRAIN 3T3; CLINICAL TRIAL; CORRELATION ANALYSIS; COW; DISEASE MARKER; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; HORMONE RELEASE; HUMAN; INHIBITION KINETICS; INSULIN SENSITIVITY; MEDICAL RESEARCH; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OXIDATIVE STRESS; PROTEIN EXPRESSION; RAT; RECEPTOR UPREGULATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; VASODILATATION; WEIGHT REDUCTION;

ADIPOCYTES; ADIPONECTIN; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; HUMANS; RISK FACTORS;

EID: 33645076524     PISSN: 15233804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11883-006-0045-5     Document Type: Review

References (54)

1. Libby P, Nathan DM, Abraham K, et al.: Report of the National Heart, Lung, and Blood Institute-National Institute of Diabetes and Digestive and Kidney Diseases Working Group on Cardiovascular Complications of Type 1 Diabetes Mellitus. Circulation 2005, 111:3489-3493.
2. Yuji M: Adipocytokines: emerging therapeutic targets. Curr Atheroscler Rep 2005, 7:58-62.
3. Maeda K, Okubo K, Shimomura I, et al.: cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (adipose most abundant gene transcript). Biochem Biophys Res Commun 1996, 221:286-289.
4. Ruana H, Lodish HF: Regulation of insulin sensitivity by adipose tissue-derived hormones and inflammatory cytokines. Curr Opin Lipidol 2004, 15:297-302.
5. Goldstein BJ, Scalia R: Vascular effects of adiponectin. J Clin Endocrinol Metab 2004, 89:2563-2568.
6. Nagashima K, Lopez C, Donovan D, et al.: Effects of the PPARgamma agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus. J Clin Invest 2005, 115:1323-1332.
7. Yamauchi T: Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003, 423:762-769.
8. Kadowaki T, Yamauchi T: Adiponectin and adiponectin receptors. Endocrine Rev 2004, 26:439-451.
9. Hsueh WA, Lyon CJ, Quinones MJ: Insulin resistance and the endothelium. Am J Med 2004, 117:109-117.
10. Chen H, Montagnani M, Funahashi T, Shimomura I: Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J Biol Chem 2003, 278:45021-45026.
11. Motoshima H, Wu X, Mahadev K, Goldstein BJ: Adiponectin suppresses proliferation and superoxide generation and enhances eNOS activity in endothelial cells treated with oxidized LDL. Biochem Biophys Res Commun 2004, 315:264-271.
12. Clasen R, Schupp M, Foryst-Ludwig A, et al.: PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectin. Hypertension 2005, 46:137-143.
13. Ross R: The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993, 362:801-809.
14. Collins T, Read MA, Neish AS, et al.: Transcriptional regulation of endothelial cell adhesion molecules: NF-kB and cytokine-inducible enhancers. FASEB J 1995, 9:899-909.
15. Brand K, Page S, Rogler G, et al.: Activated transcription factor nuclear factor-kappa B is present in the atherosclerotic lesion. J Clin Invest 1996, 97:1715-1722.
16. Kolapo M, Ajuwon R, Spurlock ME: Adiponectin inhibits LPS-induced NF-kB activation and IL-6 production and increases PPARa2 expression in adipocytes. Am J Physiol Regul Integr Comp Physiol 2005, 288:R1220-R1225.
17. Wulster-Radcliffe MC, Ajuwon KM, Wang J, et al.: Adiponectin differentially regulates cytokines in porcine macrophages. Biochem Biophys Res Commun 2004, 316:924-929.
18. Kougias P, Chai II, Lin PH, et al.: Effects of adipocyte-derived cytokines on endothelial functions: implication of vascular disease. J Surg Res 2005, 126:121-129.
19. Ouchi N, Kihara S, Arita Y, et al.: Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kB signaling through a cAMP-dependent pathway. Circulation 2000, 102:1296-1301.
20. Blake GJ, Ridker PM: Novel clinical markers of vascular wall inflammation. Circ Res 2001, 89:763-771.
21. Ouchi N, Kihara S, Funahashi T, et al.: Reciprocal association of c-reactive protein with adiponectin in blood stream and adipose tissue. Circulation 2003, 107:671-674.
22. Shimabukuro M, Higa N, Asahi T, et al.: Hypoadiponectinemia is closely linked to endothelial dysfunction in man. J Clin Endocrinol Metab 2003, 88:3236-3240.
23. Hattori S, Hattori Y, Kasai K: Hypoadiponectinemia is caused by chronic blockade of nitric oxide synthesis in rats. Metab Clin Exper 2005, 54:482-487.
24. Ouchi N, Ohishi M, Kihara S, et al.: Association of hypoadiponectinemia with impaired vasoreactivity. Hypertension 2003, 42:231-234.
25. Kubota N, Terauchi Y, Yamauchi T, et al.: Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem 2002, 277:25863-25866.
26. Matsuda M, Shimomura I, Sata M, et al.: Role of adiponectin in preventing vascular stenosis: the missing link of adipo-vascular axis. J Biol Chem 2002, 277:37487-37491.
27. Shibata R, Ouchi N, Ito M, et al.: Adiponectin-mediated modulation of hypertrophic signals in the heart. Nat Med 2004, 10:1384-1389.
28. Okamoto Y, Kihara S, Ouchi N, et al.: Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 2002, 106:2767-2770.
29. Ouchi N, Kihara S, Arita Y: Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class a scavenger receptor expression in human monocyte-derived macrophages. Circulation 2001, 103:1057-1063.
30. Ibrahimi A, Abumrad NA: Role of CD36 in membrane transport of long-chain fatty acids. Curr Opin Clin Nutr Metab Care 2002, 5:139-145.
31. Tschritter O, Fritsche A, Thamer C, et al.: Plasma adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism. Diabetes 2003, 52:239-243.
32. Weyer C, Funahashi T, Tanaka S, et al.: Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001, 86:1930-1935.
33. Chan DC, Watts GF, Theodore WK, et al.: Adiponectin and other adipocytokines as predictors of markers of triglyceride-rich lipoprotein metabolism. Clin Chem 2005, 51:578-585.
34. Schulze MB, Shai I, Rimm EB, et al.: Adiponectin and future coronary heart disease events among men with type 2 diabetes. Diabetes 2005, 54:534-539.
35. Kumada M, Kihara S, Sumitsuji S, et al., for the Osaka CAD Study Group: Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 2003, 23:85-89.
36. Maahs DM, Ogden LG, Kinney GL, et al.: Low plasma adiponectin levels predict progression of coronary artery calcification. Circulation 2005, 111:747-753.
37. Weyer C, Funahashi T, Tanaka S, et al.: Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001, 86:1930-1935.
38. Knowler WC, Pettitt DJ, Saad MF, Bennett PH: Diabetes mellitus in the Pima Indians: incidence risk factors and pathogenesis. Diab Metab Rev 1990, 6:1-27.
39. Lillioja S, Nyomba BL, Saad MF, et al.: Exaggerated early insulin release and insulin resistance in a diabetes-prone population: a metabolic comparison of Pima Indians and Caucasians. J Clin Endocrinol Metab 1991, 73:866-876.
40. Ingelfinger JA, Bennett PH, Liebow IM, Miller M: Coronary heart disease in the Pima Indians: electrocardiographic findings and postmortem evidence of myocardial infarction in a population with a high prevalence of diabetes mellitus. Diabetes 1976, 25:561-565.
41. Chan DC, Watts GF, Theodore WK, et al.: Adiponectin and other adipocytokines as predictors of markers of triglyceride-rich lipoprotein metabolism. Clin Chem 2005, 51:578-585.
42. Schulze MB, Shai I, Rimm EB, et al.: Adiponectin and future coronary heart disease events among men with type 2 diabetes. Diabetes 2005, 54:534-539.
43. Zoccali C, Mallamaci F, Tripepi G, et al.: Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 2002, 13:134-141.
44. Kumada M, Kihara S, Sumitsuji S, et al., for the Osaka CAD Study Group: Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 2003, 23:85-89.
45. Maahs DM, Ogden LG, Kinney GL, et al.: Low plasma adiponectin levels predict progression of coronary artery calcification. Circulation 2005, 111:747-753.
46. Sierksma A, Patel H, Ouchi N, et al.: Effect of moderate alcohol consumption on adiponectin, tumor necrosis factor-alpha, and insulin sensitivity. Diabetes Care 2004, 27:184-189.
47. JG Yu, Javorschi S, Hevener AL, et al.: The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes 2002, 51:2968-2974.
48. Nagashima K, Lopez C, Donovan D, et al.: Effects of the PPARgamma agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus. J Clin Invest 2005, 115:1323-1332.
49. Iwaki M, Matsuda M, Maeda N, et al.: Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes 2003, 52:1655-1663.
50. Van Gaal LF, Rissanen AM, Scheen AI, et al., for the RIO-Europe Study Group: Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005, 365:1389-1397.
51. RIO lipid ACC. http://en.sanofi-aventis.com/press/p_press_2004.asp. Accessed March 9, 2004.
52. Despres JP: RIO lipid. J Am Coll Cardiol 2005, In press.
53. Bensaid M, Gary-Bobo M, Esclangon A, et al.: The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol 2003, 63:908-914.
54. Marx N, Sukhova G, Murphy C, et al.: Macrophages in human atheroma contain PPARgamma: differentiation-dependent peroxisomal proliferator-activated receptor gamma(PPARgamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro. Am J Pathol 1998, 153:17-23.